際際滷

際際滷Share a Scribd company logo
Leukaemia I & II
General & Etiology Causes
Uncontrolled proliferation of abnormal/ malignant
clone  Replacement of normal haemopoietic cells in
the bone marrow
Bone marrow disorder.
Malignant blood disorder.
Majority of leukaemia is unknown.
Accumulation of abnormal white cells in the BM, may
cause:
BM failure
Raised circulating white cell count
Infiltrate organs
Leukaemoid reaction:
Occurrence of peripheral blood picture resembling
that of leukaemia in a subject who does not have
leukaemia
1) Ionizing radiation:
AML,CML
Irradiation therapy for other malignancies 
myelodysplasia acute leukaemia.
2) Chemicals:
Benzene, petroleum derivatives and alkylating agents
; bulsulphan, chlorambucil, chloramphenicol
3) Genetic abnormalities:
t(9,22)CML
t(15,17) acute promyelocytic leukaemia
increase incidence of leukaemia : Down's Syndrome,
Fanconi's anaemia
4) Viruses:
HTLV I  T cell leukaemia/ lymphoma
HTLV II  Hairy cell leukaemia
AML classification with morphology
AML minimally differentiated ( FAB M0)-
No evidence of myeloid differentiation by morphology and light microscopy cytochemistry
Immunophenotypic studies, essential
AML without maturation (FAB M1)-
-The blasts constitute  90% of the non-erythroid cells
- > 3% of the blasts show SBB and MPO positivity
AML with maturation ( FAB M2) -
There is evidence of maturation in 10 % or more neutrophil precursors
Acute promeylocytic leukaemia (FAB M3)
-
Acute myelomonocytic leukaemia (FAB M4)
-shows proliferation of both neutrophil and monocyte precursors
Acute monoblastic and monocytic leukaemia ( FAB M5a and M5b)-
80% or more of the leukaemic cells are of monocytic lineage, including monocytes, promonocytes and
monoblasts
Acute Erythroid leukaemia (FAB M6)-
(-erythroid /myeloid or erythroleukemia M6a (pure erythroid leukaemia M6 b)
-These leukaemias are characterized by a predominant erythroid population
Acute Leukaemia Clinical features Diagnosis & laboratory investigation Management
AML. 1. Pallor, lethargy and dyspnoea
due to anaemia
2. Fever, malaise, features of
mouth, throat, skin, respiratory,
perianal or other infections,
including septicemia due to
neutropenia
3.Spontaneous bruises, purpura,
bleeding gums, menorrhagia and
bleeding from venepuncture sites
due to thrombocytopenia
4.A bleeding tendency due to
thrombocytopenia and
disseminated intravascular
coagulation (DIC) is characteristic
of AML M3
Due to organ infiltration
1.Moderate hepatomegaly,
splenomegaly
2.Gum hypertrophy and infiltration
(M4 & 5)
3.Skin infiltration, meningeal
syndrome (AML M4 & 5)
4.Lysosymes released by the blast
cells may cause renal damage in
AML M5
.In AML M6 (erythroleukaemia), many
erythroblasts may be found in the
blood film
.In AML M3, tests for DIC are positive
.Serum uric acid and LDH may be
raised
-A normochromic normocytic anaemia
-TLC may be decreased, normal or
increased
-Thrombocytopenia
-Blood film shows variable numbers of
blast cells, the blasts may contain
auer rods
Cytochemistry:
 Myeloperoxidase ( MPO)
activity is specific for myeloid
differentiation
 Sudan Black B (SBB ) reactivity
is similar to MPO in
myeloblasts and monoblasts
 Non-specific esterase ( NSE)
reactivity is diffuse in the
cytoplasm of monoblasts
Immunophenotype
 Immunophenotypic analysis
has a central role to
differentiate between AML-
M0 and ALL
 It may be performed
 By flow cytometry or
immunohistochemistry on the
slides
-Inform the patient /
family
-Start treatment ASAP
-Supportive care /
associated problems
-Remission Induction
cytotoxic chemotheray
-Remission
maintenance therapy
ALL Clinical features Laboratory investigation Management
-Common form of
leukemia in children
-incidence is highest
at, 3-4 years
-The common (CD10+
)
precursor B type, has
an equal sex incidence
ALL, L1: blast cells
are small, uniform,
high N:C ratio,
inconspicuous nucleoli
ALL, L2:
heterogeneous
population,
some blast cells larger
with lower N:C ratio
some are like those in
L1with high N:C ratio
ALL, L3: large cells
having vacuolated and
basophilic cytoplasm (
usually B-ALL ),
nucleoli prominent
Symptoms due to bone marrow
failure
1.Bone pain and arthralgia
2.Lymphadenopathy,
hepatomegaly and splenomegaly
are frequent
3.Meningeal syndrome:
- headache, nausea, vomiting ,
blurring of vision and diplopia
4.Testicular swelling
 Peripheral blood film and
CBC/FBC
 Bone marrow
examination, which in case
of acute leukaemias, is
hypercellular with marked
proliferation of blasts
 Lumbar puncture in
patients with meningeal
leukaemias
X-ray
- may reveal lytic bone lesions
mediastinal mass due to
enlargement of thymus/ and or
mediastinal lymph nodes
-Immunological markers and
chromosome analysis
 Supportive care:
 (Metabolic
complications,
hyperleucytosis,
infection control,
haematologic
support)
 Risk assessment
 Induction
chemotherapy, CNS
prophylaxis
 Consolidation
cemotherapy
 Maintenance
chemotherapy
.
Chronic lymphocytic
leukaemia
Proliferation and
accumulation of a
monoclonal
population of
abnormal lymphocyte
Express CD5 and CD23
Common in west
Elderly >50 y/o
Male> female
Majority: B-cell type
(95%)
Most patient asymptomatic
-Anaemia
-Lymphadenopathy (symmetrical
and painless)
-Immunological failure
-Splenomegaly & hepatomegaly
- autoimmune hemolytic anaemia
(10%)
-immune thrombocytopenia (ITP) -
5%
- haemorrhagic manisfestation
FBC: lymphocytosis
Smudge or smear cells
Normochromic normocytic
anaemia
BM biopsy: increase lymphocytes
Clonality study:
-immunotyping
-molecular analysis (IgG/TCR gene
rearrangement studies)
-chemotherapy
- monoclonal antibodies
Chronic Leukaemia Clinical features Laboratory
investigation
Management
Chronic Myeloid
Leukaemia
A clonal
myeloproliferative
disorder rise from an
acquired genetic
change in pluripotent
stem cell
-overproduction of
neutrophils and its
precursor
Philadelphia
chromosome
-t(9,22)(q34,11)
95% CML; Ph' +ve
Fusion BCR-ABL genes
Has greater tyrosine
kinase
1) Chronic phase
- adult (40-60)
- anaemia
-splenomegaly
- hepatomegaly
- gout
(hyperuricaemia)
- hyperviscosity
syndrome (due to
leucocytosis)
- neutropenia,
thrombocytopenia
(not common)
2) Blast crisis
Transform  acute
leukaemia, mostly AML
Chronic phase
FBP: Leucocytosis
(increased WBC)
Usually >100  109
/l
Morphology: Myeloid
cells at all stages of
differentiation
Bone Marrow:
Hypercellular
Myelopoiesis is
increased (with few
blast is < 5%)
Neutrophil alkaline
phosphatase (NAP)
score : reduced
Cytogenetic analysis:
Ph-chromosome
Molecular analysis:
BCR-ABL fusion gene.
Chronic phase:
Hydorxyurea, Glivec/
Imatinib
Transplantation
- bone marrow /
peripheral blood stem
cell transplant.
Chronic lymphocytic
leukaemia
Proliferation and
accumulation of a
monoclonal population
of abnormal
lymphocyte
Express CD5 and CD23
Common in west
Elderly >50 y/o
Male> female
Majority: B-cell type
(95%)
Most patient
asymptomatic
-Anaemia
-Lymphadenopathy
(symmetrical and
painless)
-Immunological failure
-Splenomegaly &
hepatomegaly
- autoimmune
hemolytic anaemia
(10%)
-immune
thrombocytopenia
(ITP) -5%
- haemorrhagic
manisfestation
FBC: lymphocytosis
Smudge or smear cells
Normochromic
normocytic anaemia
BM biopsy: increase
lymphocytes
Clonality study:
-immunotyping
-molecular analysis
(IgG/TCR gene
rearrangement
studies)
-chemotherapy
- monoclonal
antibodies

More Related Content

Leukaemia i

  • 1. Leukaemia I & II General & Etiology Causes Uncontrolled proliferation of abnormal/ malignant clone Replacement of normal haemopoietic cells in the bone marrow Bone marrow disorder. Malignant blood disorder. Majority of leukaemia is unknown. Accumulation of abnormal white cells in the BM, may cause: BM failure Raised circulating white cell count Infiltrate organs Leukaemoid reaction: Occurrence of peripheral blood picture resembling that of leukaemia in a subject who does not have leukaemia 1) Ionizing radiation: AML,CML Irradiation therapy for other malignancies myelodysplasia acute leukaemia. 2) Chemicals: Benzene, petroleum derivatives and alkylating agents ; bulsulphan, chlorambucil, chloramphenicol 3) Genetic abnormalities: t(9,22)CML t(15,17) acute promyelocytic leukaemia increase incidence of leukaemia : Down's Syndrome, Fanconi's anaemia 4) Viruses: HTLV I T cell leukaemia/ lymphoma HTLV II Hairy cell leukaemia AML classification with morphology AML minimally differentiated ( FAB M0)- No evidence of myeloid differentiation by morphology and light microscopy cytochemistry Immunophenotypic studies, essential AML without maturation (FAB M1)- -The blasts constitute 90% of the non-erythroid cells - > 3% of the blasts show SBB and MPO positivity AML with maturation ( FAB M2) - There is evidence of maturation in 10 % or more neutrophil precursors Acute promeylocytic leukaemia (FAB M3) - Acute myelomonocytic leukaemia (FAB M4) -shows proliferation of both neutrophil and monocyte precursors Acute monoblastic and monocytic leukaemia ( FAB M5a and M5b)- 80% or more of the leukaemic cells are of monocytic lineage, including monocytes, promonocytes and monoblasts Acute Erythroid leukaemia (FAB M6)- (-erythroid /myeloid or erythroleukemia M6a (pure erythroid leukaemia M6 b) -These leukaemias are characterized by a predominant erythroid population
  • 2. Acute Leukaemia Clinical features Diagnosis & laboratory investigation Management AML. 1. Pallor, lethargy and dyspnoea due to anaemia 2. Fever, malaise, features of mouth, throat, skin, respiratory, perianal or other infections, including septicemia due to neutropenia 3.Spontaneous bruises, purpura, bleeding gums, menorrhagia and bleeding from venepuncture sites due to thrombocytopenia 4.A bleeding tendency due to thrombocytopenia and disseminated intravascular coagulation (DIC) is characteristic of AML M3 Due to organ infiltration 1.Moderate hepatomegaly, splenomegaly 2.Gum hypertrophy and infiltration (M4 & 5) 3.Skin infiltration, meningeal syndrome (AML M4 & 5) 4.Lysosymes released by the blast cells may cause renal damage in AML M5 .In AML M6 (erythroleukaemia), many erythroblasts may be found in the blood film .In AML M3, tests for DIC are positive .Serum uric acid and LDH may be raised -A normochromic normocytic anaemia -TLC may be decreased, normal or increased -Thrombocytopenia -Blood film shows variable numbers of blast cells, the blasts may contain auer rods Cytochemistry: Myeloperoxidase ( MPO) activity is specific for myeloid differentiation Sudan Black B (SBB ) reactivity is similar to MPO in myeloblasts and monoblasts Non-specific esterase ( NSE) reactivity is diffuse in the cytoplasm of monoblasts Immunophenotype Immunophenotypic analysis has a central role to differentiate between AML- M0 and ALL It may be performed By flow cytometry or immunohistochemistry on the slides -Inform the patient / family -Start treatment ASAP -Supportive care / associated problems -Remission Induction cytotoxic chemotheray -Remission maintenance therapy
  • 3. ALL Clinical features Laboratory investigation Management -Common form of leukemia in children -incidence is highest at, 3-4 years -The common (CD10+ ) precursor B type, has an equal sex incidence ALL, L1: blast cells are small, uniform, high N:C ratio, inconspicuous nucleoli ALL, L2: heterogeneous population, some blast cells larger with lower N:C ratio some are like those in L1with high N:C ratio ALL, L3: large cells having vacuolated and basophilic cytoplasm ( usually B-ALL ), nucleoli prominent Symptoms due to bone marrow failure 1.Bone pain and arthralgia 2.Lymphadenopathy, hepatomegaly and splenomegaly are frequent 3.Meningeal syndrome: - headache, nausea, vomiting , blurring of vision and diplopia 4.Testicular swelling Peripheral blood film and CBC/FBC Bone marrow examination, which in case of acute leukaemias, is hypercellular with marked proliferation of blasts Lumbar puncture in patients with meningeal leukaemias X-ray - may reveal lytic bone lesions mediastinal mass due to enlargement of thymus/ and or mediastinal lymph nodes -Immunological markers and chromosome analysis Supportive care: (Metabolic complications, hyperleucytosis, infection control, haematologic support) Risk assessment Induction chemotherapy, CNS prophylaxis Consolidation cemotherapy Maintenance chemotherapy . Chronic lymphocytic leukaemia Proliferation and accumulation of a monoclonal population of abnormal lymphocyte Express CD5 and CD23 Common in west Elderly >50 y/o Male> female Majority: B-cell type (95%) Most patient asymptomatic -Anaemia -Lymphadenopathy (symmetrical and painless) -Immunological failure -Splenomegaly & hepatomegaly - autoimmune hemolytic anaemia (10%) -immune thrombocytopenia (ITP) - 5% - haemorrhagic manisfestation FBC: lymphocytosis Smudge or smear cells Normochromic normocytic anaemia BM biopsy: increase lymphocytes Clonality study: -immunotyping -molecular analysis (IgG/TCR gene rearrangement studies) -chemotherapy - monoclonal antibodies
  • 4. Chronic Leukaemia Clinical features Laboratory investigation Management Chronic Myeloid Leukaemia A clonal myeloproliferative disorder rise from an acquired genetic change in pluripotent stem cell -overproduction of neutrophils and its precursor Philadelphia chromosome -t(9,22)(q34,11) 95% CML; Ph' +ve Fusion BCR-ABL genes Has greater tyrosine kinase 1) Chronic phase - adult (40-60) - anaemia -splenomegaly - hepatomegaly - gout (hyperuricaemia) - hyperviscosity syndrome (due to leucocytosis) - neutropenia, thrombocytopenia (not common) 2) Blast crisis Transform acute leukaemia, mostly AML Chronic phase FBP: Leucocytosis (increased WBC) Usually >100 109 /l Morphology: Myeloid cells at all stages of differentiation Bone Marrow: Hypercellular Myelopoiesis is increased (with few blast is < 5%) Neutrophil alkaline phosphatase (NAP) score : reduced Cytogenetic analysis: Ph-chromosome Molecular analysis: BCR-ABL fusion gene. Chronic phase: Hydorxyurea, Glivec/ Imatinib Transplantation - bone marrow / peripheral blood stem cell transplant. Chronic lymphocytic leukaemia Proliferation and accumulation of a monoclonal population of abnormal lymphocyte Express CD5 and CD23 Common in west Elderly >50 y/o Male> female Majority: B-cell type (95%) Most patient asymptomatic -Anaemia -Lymphadenopathy (symmetrical and painless) -Immunological failure -Splenomegaly & hepatomegaly - autoimmune hemolytic anaemia (10%) -immune thrombocytopenia (ITP) -5% - haemorrhagic manisfestation FBC: lymphocytosis Smudge or smear cells Normochromic normocytic anaemia BM biopsy: increase lymphocytes Clonality study: -immunotyping -molecular analysis (IgG/TCR gene rearrangement studies) -chemotherapy - monoclonal antibodies